Well the injectable market has grown substantially over the last 5-10 years and with that growth has come the evaluation of the products we use. Now in some cases that evolution has just been rebranding but in many cases companies are producing new versions of tried products with better technology and thus improved use profiles. Every now and then a product comes out of no where in the injectable market and changes the way we think about certain things. Kybella® is one such product!!
Historically the only way to treat excess fat deposits in the face and neck has been surgical removal either via closed procedures (think Liposuction) or open procedures (think Facelift, Neck lift, Open Lips etc). However, more and more patients are coming to the cosmetic market though at younger ages, many with little interest in surgical procedures. For these patients and others Kybella® offers a wonderful upside, Fat removal without surgery!
So What is Kybella®?? Kybella is a synthetic deoxycholic acid. This acid normally occurs naturally in the body is crucial for metabolizing and absorbing dietary fats. When injected Deoxycholic acid acts to destroy fat cells via “lipolysis” and thus reduce fullness under the chin. Theoretically once these cells are destroyed the fat storage potential is decreased and future fat deposition should be significantly diminished
So the next question most people want to know as both patients and providers is how is this stuff administered. We have gone ahead and prepared a video detailing the injection technique for Kybella. I hope you enjoy it!! Please feel free to send an any questions you may have to [email protected]
Dr J Marshall Green III DDS
Cosmetic and Reconstructive Facial Surgery
Hampton Roads, Virginia
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Important Safety Information
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Warnings and Precautions
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
Please see KYBELLA® full prescribing information.